Imfinzi
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
AstraZeneca’s Imfinzi gets orphan drug designation from FDA
July 12, 2019Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …
AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer
June 27, 2019Research and Development AstraZeneca, Imfinzi, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer
November 16, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer
June 22, 2018Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma
In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …
AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer
May 25, 2018Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …
AZ’s combo woes continue, with failure in lung cancer
April 24, 2018Manufacturing and Production, Research and Development AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …
Adaxis-AZ immunotherapy combo hit by clinical hold after death
March 13, 2018Manufacturing and Production, Research and Development Adaxis, AstraZeneca, Imfinzi, biotech, drugs, immunotherapy, pharma, pharmaceutical
Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …
AZ’s Imfinzi seals blockbuster lung cancer market with FDA nod
February 19, 2018Sales and Marketing AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …
AZ’s Imfinzi scores FDA breakthrough therapy designation in wake of major trial failure
July 31, 2017Sales and Marketing AstraZeneca, Imfinzi, drugs, healthcare, mystic, phaarmaceutical, pharma
Still reeling from the public reaction to the flop of its key Mystic trial, where its injectable immunotherapy drug Imfinzi …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
